On MYC ? Well using the company's own timelines they have H12015 Cell Based H22015 Mice - i'd assume a deal there would be markedly different depending on which of those two it was reached at but probably falls around the same mark in the long run maybe a bit shorter if it comes earlier.
But that still leaves open many other factors to increase value prior with successfully delivery of big pharma's existing drugs through EET or Genentech advancement < still wonder how advanced that is ? are they actually screening phylomers for new drug candidates against antimicrobial targets or is it about delivering drugs they already have in development ? one is a much quicker path than the other.
Company had exciting anticipation of new deal(S) by 1H2015 would love to see one with an equity stake that would be a big driver for the company if they named a good price for that equity to go out at.
To be honest I've never really got Peptidreams value or discrepancies between the two. The company's weren't actually standing much differently in terms of partners at the time & all preclinical but they were holding over $50M in cash which gives it a lot of ground. I think a lot of it has to do with the restriction they shaved off less than 20% of the company in the IPO keep it all pretty tightly locked up.
PYC Price at posting:
2.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)